Category - News

Executive Moves

Aaron Davidson named CFO and SVP corporate development of Profound Medical

Profound Medical (TSXV:PRN; OTCQX:PRFMF) strengthened its management team, naming Aaron Davidson as CFO and SVP of corporate development, effective May 3, 2018. In a statement, Arun Menawat, CEO, said Mr. Davidson’s...

May 1, 2018

Markets

Leerink ups Karyopharm Therapeutics PT to $24 from $19

Leerink raised its price target for Karyopharm Therapeutics (NASDAQ:KPTI) to $24 from $19 after the company announced top-line results from the Phase 2b STORM study, evaluating selinexor with low dose dexamethasone in...

May 1, 2018

Executive Moves

Maxim Group expands biotech equity research team

Maxim Group expanded its equity research platform with the appointment of Caroline Palomeque as a SVP and a senior biotechnology analyst.

April 30, 2018

Markets

WB starts Viking Therapeutics at OP

William Blair launched coverage of Viking Therapeutics (NASDAQ:VKTX) with an “outperform” rating. The stock closed at $3.97 on April 27. Viking has a differentiated clinical pipeline focusing on modulating hormone...

April 30, 2018

Markets

Ladenburg starts Dova Pharma at buy; PT $65

Ladenburg Thalmann initiated coverage of Dova Pharmaceuticals (NASDAQ:DOVA) with a “buy” rating and $65 price target. The stock was quoted at $26.55 near the close on April 26. Dova is focused on the development and...

April 26, 2018

Developments

Saniona moving to second part of Phase 2a study in Prader-Willi Syndrome

Closely-held Saniona of Denmark has obtained approval to initiate the second part of its Phase 2a trial for Tesomet in adolescents with Prader-Willi syndrome (PWS), the most common genetic cause of life-threatening...

April 26, 2018

Developments

Adocia and Tonghua Dongbao in insulin strategic alliance in China

Adocia (Euronext Paris:FR0011184241 – ADOC) and Tonghua Dongbao Pharmaceuticals (Shanghai Stock Exchange 600867) announced a strategic partnership, giving Tonghua exclusive development and commercialization rights in...

April 26, 2018

Markets

BTIG cuts Prothena to neutral; discontinues PT

BTIG downgraded Prothena (NASDAQ:PRTA) to “neutral” without a price target after the company discontinued development of NEOD001, an investigational antibody being evaluated to treat AL amyloidosis. The stock dropped...

April 24, 2018

Markets

Mackie cuts Cipher Pharma PT to $5.30 from $7.10

Mackie Research Capital lowered its price target for Cipher Pharmaceuticals (TSX:CPH) to $5.30 from $7.10 after the company lowered first quarter expectations on the back of weak Absorica sales. Analyst Andre Uddin...

April 24, 2018

Markets

BTIG starts Homology Medicines at buy; PT $35

BTIG initiated coverage of Homology Medicines (NASDAQ:FIXX) with a “buy” rating and $35 price target. The stock closed at $19.90 on April 23. Founded in 2015, Homology is a genetic medicine company that is focused on...

April 24, 2018

Category - News

Subscribe